VERTEX PHARMACEUTICALS INC
Reported by Provident Investment Management Inc
Reported 131,577 shares, down 9,151 (6.5%) from the prior quarter.
Reported value -1.6%; share count -6.5% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-12-31 | 40665000 |
| 2022-03-31 | 48883000 |
| 2022-06-30 | 47722000 |
| 2022-09-30 | 46913000 |
| 2022-12-31 | 46414743 |
| 2023-03-31 | 51370273 |
| 2023-06-30 | 57090007 |
| 2023-09-30 | 56044908 |
| 2023-12-31 | 65232198 |
| 2024-03-31 | 66933851 |
| 2024-06-30 | 74930517 |
| 2024-09-30 | 72322265 |
| 2024-12-31 | 62445078 |
| 2025-03-31 | 75789487 |
| 2025-06-30 | 70656356 |
| 2025-09-30 | 60079926 |
| 2025-12-31 | 67667607 |
| 2026-03-31 | 65918235 |
| 2026-06-30 | 69903819 |
| 2026-09-30 | 68789881 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Reduced | 131,577 | -9,151 (-6.5%) | 6.89% | $68,789,881 | 2026-10-23 | |
| Q2 2026 | Reduced | 140,728 | -6,892 (-4.7%) | 6.79% | $69,903,819 | 2026-08-11 | |
| Q1 2026 | Reduced | 147,620 | -1,638 (-1.1%) | 6.55% | $65,918,235 | 2026-05-13 | |
| Q4 2025 | Reduced | 149,258 | -4,148 (-2.7%) | 6.16% | $67,667,607 | 2026-02-04 | |
| Q3 2025 | Reduced | 153,406 | -5,301 (-3.3%) | 5.3% | $60,079,926 | 2025-11-19 | |
| Q2 2025 | Added | 158,707 | +2,382 (1.5%) | 6.04% | $70,656,356 | 2025-08-26 | |
| Q1 2025 | Added | 156,325 | +1,259 (0.8%) | 7.14% | $75,789,487 | 2025-05-09 | |
| Q4 2024 | Reduced | 155,066 | -439 (-0.3%) | 5.96% | $62,445,078 | 2025-02-12 | |
| Q3 2024 | Reduced | 155,505 | -4,357 (-2.7%) | 6.45% | $72,322,265 | 2024-11-12 | |
| Q2 2024 | Reduced | 159,862 | -263 (-0.2%) | 6.82% | $74,930,517 | 2024-08-07 | |
| Q1 2024 | Reduced | 160,125 | -194 (-0.1%) | 5.9% | $66,933,851 | 2024-05-14 | |
| Q4 2023 | Reduced | 160,319 | -850 (-0.5%) | 6.16% | $65,232,198 | 2024-02-12 | |
| Q3 2023 | Reduced | 161,169 | -1,060 (-0.7%) | 6.18% | $56,044,908 | 2023-11-14 | |
| Q2 2023 | Reduced | 162,229 | -815 (-0.5%) | 6.04% | $57,090,007 | 2023-08-09 | |
| Q1 2023 | Added | 163,044 | +2,317 (1.4%) | 5.57% | $51,370,273 | 2023-05-15 | |
| Q4 2022 | Reduced | 160,727 | -1,300 (-0.8%) | 5.5% | $46,414,743 | 2023-02-13 | |
| Q3 2022 | Reduced | 162,027 | -7,328 (-4.3%) | 6.01% | $46,913,000 | 2022-11-17 | |
| Q2 2022 | Reduced | 169,355 | -17,959 (-9.6%) | 5.62% | $47,722,000 | 2022-08-11 | |
| Q1 2022 | Added | 187,314 | +2,135 (1.2%) | 4.68% | $48,883,000 | 2022-05-16 | |
| Q4 2021 | Added | 185,179 | +1,813 (1.0%) | 3.67% | $40,665,000 | 2022-02-11 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
1903 managers reported VERTEX PHARMACEUTICALS INC for Q3 2026.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| Capital World Investors | Reduced | 25,966,793 | -148,221 | 1.65% | $13,575,850,288 | 54 qtrs |
| BlackRock Inc | Reduced | 23,803,111 | -306,262 | 0.18% | $12,444,504,450 | 9 qtrs |
| Capital Research Global Investors | Reduced | 17,814,302 | -1,676,335 | 1.32% | $9,313,657,644 | 15 qtrs |
| VANGUARD CAPITAL MANAGEMENT LLC | Added | 16,595,978 | +15,265 | 0.18% | $8,676,543,258 | 3 qtrs |
| STATE STREET CORPORATION | Added | 12,024,456 | +152,997 | 0.18% | $6,286,505,841 | 54 qtrs |
| Invesco Ltd | Added | 8,280,998 | +237,946 | 0.34% | $4,329,388,595 | 54 qtrs |
| GEODE CAPITAL MANAGEMENT LLC | Added | 6,081,969 | +64,121 | 0.16% | $3,165,506,588 | 54 qtrs |
| JPMorgan Chase & Co | Reduced | 5,691,686 | -825,914 | 0.16% | $2,997,982,781 | 54 qtrs |
| Capital International Investors | Added | 5,059,186 | +364,042 | 0.55% | $2,645,058,681 | 8 qtrs |
| VANGUARD PORTFOLIO MANAGEMENT LLC | Added | 4,944,618 | +65,631 | 0.12% | $2,585,095,737 | 3 qtrs |
Filing details and methodology As reported
- Report period
- September 30, 2026
- Filed
- October 23, 2026
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
- Sole
- 0
- Shared
- 0
- None
- 131,577
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.